Lowest-Rated StocksLowest-RatedMost-Downgraded StocksMost-DowngradedNASDAQ:PTCT PTC Therapeutics (PTCT) Stock Forecast, Price & News $25.53 -0.15 (-0.58%) (As of 09/20/2023 ET) Add Compare Share Share Today's Range$25.43▼$26.8950-Day Range$24.28▼$41.8052-Week Range$23.57▼$59.84Volume1.34 million shsAverage Volume1.13 million shsMarket Capitalization$1.92 billionP/E RatioN/ADividend YieldN/APrice Target$39.57 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability PTC Therapeutics MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside55.0% Upside$39.57 Price TargetShort InterestBearish9.82% of Shares Sold ShortDividend StrengthN/ASustainability-1.38Upright™ Environmental ScoreNews Sentiment-0.21Based on 50 Articles This WeekInsider TradingSelling Shares$465,007 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($5.46) to ($4.34) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.01 out of 5 starsMedical Sector556th out of 961 stocksPharmaceutical Preparations Industry257th out of 455 stocks 4.0 Analyst's Opinion Consensus RatingPTC Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 7 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $39.57, PTC Therapeutics has a forecasted upside of 55.0% from its current price of $25.53.Amount of Analyst CoveragePTC Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted9.82% of the outstanding shares of PTC Therapeutics have been sold short.Short Interest Ratio / Days to CoverPTC Therapeutics has a short interest ratio ("days to cover") of 11.9, which indicates bearish sentiment.Change versus previous monthShort interest in PTC Therapeutics has recently increased by 2.64%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldPTC Therapeutics does not currently pay a dividend.Dividend GrowthPTC Therapeutics does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorePTC Therapeutics has received a 67.15% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Lipid-lowering medication (C10)", "Glucocorticoids", "Clinical research services for infectious diseases", and "Neuromuscular disorders medication" products. See details.Environmental SustainabilityThe Environmental Impact score for PTC Therapeutics is -1.38. Previous Next 1.6 News and Social Media Coverage News SentimentPTC Therapeutics has a news sentiment score of -0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 50 news articles for PTC Therapeutics this week, compared to 4 articles on an average week.Search Interest3 people have searched for PTCT on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added PTC Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, PTC Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $465,007.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of PTC Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for PTC Therapeutics are expected to grow in the coming year, from ($5.46) to ($4.34) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of PTC Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PTC Therapeutics is -3.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About PTC Therapeutics (NASDAQ:PTCT) StockPTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.Read More PTCT Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PTCT Stock News HeadlinesSeptember 21, 2023 | americanbankingnews.comPTC Therapeutics, Inc. (NASDAQ:PTCT) to Post Q3 2023 Earnings of ($1.31) Per Share, Leerink Partnrs ForecastsSeptember 20, 2023 | finance.yahoo.comPTC Therapeutics (PTCT) Surges 5.8%: Is This an Indication of Further Gains?September 21, 2023 | Wall Street Fundamentals (Ad)How is This "Hidden Gem" Thriving in a Turbulent Market?While Wall Street flounders and giants like Amazon & Microsoft lay off thousands... One overlooked company has been quietly achieving over 400% growth. How? By buying, building, and scaling a portfolio of promising brands in high-margin, recession-resistant verticals.September 20, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Lowered to $23.00 at Bank of AmericaSeptember 20, 2023 | americanbankingnews.comFY2027 EPS Estimates for PTC Therapeutics, Inc. Lowered by Analyst (NASDAQ:PTCT)September 19, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: PTC Therapeutics (PTCT) and Werewolf Therapeutics (HOWL)September 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Cut to $26.00September 19, 2023 | americanbankingnews.comJPMorgan Chase & Co. Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $53.00September 21, 2023 | Edge On The Street (Ad)Is Gold Really Boring?Many investors perceive gold as a "boring" investment. But according to MoneyWeek, that's a good thing. Gold helps investors sleep soundly as it preserves wealth and creates a hedge against inflation. Today, there's a unique way to invest in gold, with real advantages over coins and mining stocks. September 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given New $26.00 Price Target at BarclaysSeptember 19, 2023 | americanbankingnews.comMorgan Stanley Lowers PTC Therapeutics (NASDAQ:PTCT) Price Target to $31.00September 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Given New $22.00 Price Target at The Goldman Sachs GroupSeptember 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Cut to $45.00September 19, 2023 | americanbankingnews.comCitigroup Lowers PTC Therapeutics (NASDAQ:PTCT) to NeutralSeptember 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Price Target Cut to $30.00 by Analysts at SVB LeerinkSeptember 19, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Shares Gap Down on Analyst DowngradeSeptember 18, 2023 | msn.comCitigroup Downgrades PTC Therapeutics (PTCT)September 17, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Lowered to Underperform at Raymond JamesSeptember 17, 2023 | americanbankingnews.comRaymond James Downgrades PTC Therapeutics (NASDAQ:PTCT) to UnderperformSeptember 17, 2023 | americanbankingnews.comPTC Therapeutics (NASDAQ:PTCT) Reaches New 1-Year Low at $24.43September 16, 2023 | americanbankingnews.comPTC Therapeutics Target of Unusually Large Options Trading (NASDAQ:PTCT)September 15, 2023 | markets.businessinsider.comGoldman Sachs Keeps Their Sell Rating on PTC Therapeutics (PTCT)September 15, 2023 | finance.yahoo.comBiotech Crashes 30% After European Regulators Yank Approval For Muscle Disease DrugSeptember 15, 2023 | benzinga.comPTC Therapeutics, Planet Fitness, Kemper And Other Big Stocks Moving Lower On FridaySeptember 15, 2023 | proactiveinvestors.comPTC Therapeutics slumps on European snub for DMD drugSeptember 15, 2023 | finance.yahoo.comBiotech Crashes 28% After European Regulators Yank Approval For Muscle Disease DrugSeptember 15, 2023 | stockhouse.comCHMP Delivers Opinion on Translarna(TM) for Conversion to Full AuthorizationSee More Headlines Receive PTCT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PTC Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PTCT Company Calendar Last Earnings8/03/2023Today9/21/2023Next Earnings (Estimated)10/26/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:PTCT CUSIPN/A CIK1070081 Webwww.ptcbio.com Phone(908) 222-7000Fax908-222-7231Employees1,410Year FoundedN/APrice Target and Rating Average Stock Price Forecast$39.57 High Stock Price Forecast$73.00 Low Stock Price Forecast$22.00 Forecasted Upside/Downside+55.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage13 Analysts Profitability EPS (Most Recent Fiscal Year)($8.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-559,020,000.00 Net Margins-75.49% Pretax Margin-84.20% Return on EquityN/A Return on Assets-39.69% Debt Debt-to-Equity RatioN/A Current Ratio1.24 Quick Ratio1.17 Sales & Book Value Annual Sales$698.80 million Price / Sales2.75 Cash FlowN/A Price / Cash FlowN/A Book Value($4.76) per share Price / Book-5.36Miscellaneous Outstanding Shares75,350,000Free Float71,352,000Market Cap$1.92 billion OptionableOptionable Beta0.37 7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed InvestorsAs the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.Get This Free Report Key ExecutivesDr. Matthew B. Klein F.A.C.S. (Age 51)FACS, M.D., M.S., MS, CEO & Director Comp: $995.4kDr. Stuart W. Peltz Ph.D. (Age 63)Co-Founder, Sr. Consultant & Member of Scientific Advisory Board Comp: $1.54MDr. Allan Steven Jacobson Ph.D. (Age 77)Co-Founder, Chairman of Scientific Advisory Board & Independent Director Comp: $145kDr. Neil Almstead Ph.D. (Age 56)Chief Technical Operations Officer Comp: $829.97kMr. Eric Pauwels (Age 62)Chief Bus. Officer Comp: $847.67kMr. Pierre Gravier (Age 38)Chief Financial Officer Ms. Christine Utter (Age 45)Sr. VP, Chief Accounting Officer & Head of People Services Ms. Ellen Welch Ph.D.Chief Scientific OfficerAlex KaneInvestor Relations OfficerMr. Mark Elliott Boulding (Age 62)Exec. VP & Chief Legal Officer More ExecutivesKey CompetitorsMirati TherapeuticsNASDAQ:MRTXRocket PharmaceuticalsNASDAQ:RCKTDynavax TechnologiesNASDAQ:DVAXCureVacNASDAQ:CVACGemini TherapeuticsNASDAQ:GMTXView All CompetitorsInsiders & InstitutionsAlethia YoungSold 11,666 sharesTotal: $465,006.76 ($39.86/share)Wolverine Trading LLCSold 200 shares on 8/23/2023Ownership: 0.000%Virginia Retirement Systems ET ALBought 12,700 shares on 8/22/2023Ownership: 0.017%Teachers Retirement System of The State of KentuckySold 3,881 shares on 8/21/2023Ownership: 0.125%California State Teachers Retirement SystemSold 949 shares on 8/21/2023Ownership: 0.109%View All Insider TransactionsView All Institutional Transactions PTCT Stock - Frequently Asked Questions Should I buy or sell PTC Therapeutics stock right now? 13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for PTC Therapeutics in the last year. There are currently 3 sell ratings, 7 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" PTCT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PTCT, but not buy additional shares or sell existing shares. View PTCT analyst ratings or view top-rated stocks. What is PTC Therapeutics' stock price forecast for 2023? 13 Wall Street analysts have issued 1-year target prices for PTC Therapeutics' shares. Their PTCT share price forecasts range from $22.00 to $73.00. On average, they expect the company's share price to reach $39.57 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price. View analysts price targets for PTCT or view top-rated stocks among Wall Street analysts. How have PTCT shares performed in 2023? PTC Therapeutics' stock was trading at $38.17 at the beginning of 2023. Since then, PTCT shares have decreased by 33.1% and is now trading at $25.53. View the best growth stocks for 2023 here. When is PTC Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023. View our PTCT earnings forecast. How were PTC Therapeutics' earnings last quarter? PTC Therapeutics, Inc. (NASDAQ:PTCT) posted its quarterly earnings results on Thursday, August, 3rd. The biopharmaceutical company reported ($2.66) EPS for the quarter, missing analysts' consensus estimates of ($1.58) by $1.08. The biopharmaceutical company earned $213.80 million during the quarter, compared to the consensus estimate of $206.99 million. PTC Therapeutics's quarterly revenue was up 29.2% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($2.13) earnings per share. What ETFs hold PTC Therapeutics' stock? ETFs with the largest weight of PTC Therapeutics (NASDAQ:PTCT) stock in their portfolio include Direxion mRNA ETF (MSGR), iShares Neuroscience and Healthcare ETF (IBRN), Motley Fool Small-Cap Growth ETF (TMFS), MFAM Small-Cap Growth ETF (MFMS), Invesco Biotechnology & Genome ETF (PBE), Virtus LifeSci Biotech Products ETF (BBP), Franklin Genomic Advancements ETF (HELX) and SPDR S&P Biotech ETF (XBI). What guidance has PTC Therapeutics issued on next quarter's earnings? PTC Therapeutics issued an update on its FY 2023 earnings guidance on Wednesday, July, 19th. The company provided EPS guidance of for the period. The company issued revenue guidance of $940.00M-$1.00 billion, compared to the consensus revenue estimate of $961.42 million. What is Stuart W. Peltz's approval rating as PTC Therapeutics' CEO? 24 employees have rated PTC Therapeutics Chief Executive Officer Stuart W. Peltz on Glassdoor.com. Stuart W. Peltz has an approval rating of 77% among the company's employees. What other stocks do shareholders of PTC Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other PTC Therapeutics investors own include Baidu (BIDU), Sarepta Therapeutics (SRPT), Alibaba Group (BABA), GW Pharmaceuticals (GWPH), Bausch Health Companies (BHC), NVIDIA (NVDA), Cisco Systems (CSCO), Regulus Therapeutics (RGLS), Aduro Biotech (ADRO) and Gilead Sciences (GILD). What is PTC Therapeutics' stock symbol? PTC Therapeutics trades on the NASDAQ under the ticker symbol "PTCT." Who are PTC Therapeutics' major shareholders? PTC Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include State Street Corp (4.21%), Geode Capital Management LLC (1.94%), Bank of New York Mellon Corp (1.28%), JPMorgan Chase & Co. (1.23%), Cowen AND Company LLC (1.08%) and Northern Trust Corp (0.91%). Insiders that own company stock include Alethia Young, Allan Steven Jacobson, Christine Marie Utter, David P Southwell, Dawn Svoronos, Emily Luisa Hill, Emma Reeve, Eric Pauwels, Mark Elliott Boulding, Matthew B Klein, Matthew B Klein, Neil Gregory Almstead, Stephanie Okey and Stuart Walter Peltz. View institutional ownership trends. How do I buy shares of PTC Therapeutics? Shares of PTCT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is PTC Therapeutics' stock price today? One share of PTCT stock can currently be purchased for approximately $25.53. How much money does PTC Therapeutics make? PTC Therapeutics (NASDAQ:PTCT) has a market capitalization of $1.92 billion and generates $698.80 million in revenue each year. The biopharmaceutical company earns $-559,020,000.00 in net income (profit) each year or ($8.42) on an earnings per share basis. How many employees does PTC Therapeutics have? The company employs 1,410 workers across the globe. How can I contact PTC Therapeutics? PTC Therapeutics' mailing address is 100 CORPORATE COURT, SOUTH PLAINFIELD NJ, 07080. The official website for the company is www.ptcbio.com. The biopharmaceutical company can be reached via phone at (908) 222-7000, via email at ehill@ptcbio.com, or via fax at 908-222-7231. This page (NASDAQ:PTCT) was last updated on 9/21/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PTC Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.